SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
September 1, 2010
NEOGENOMICS, INC.
(Exact name of registrant as specified in its charter)
| Nevada | 333-72097 | 74-2897368 |
| (State or other jurisdiction of | (Commission File Number) | (I.R.S. Employer |
| incorporation) | | Identification No.) |
| | | |
12701 Commonwealth Drive, Suite 9, Fort Myers, Florida (Address of principal executive offices) | 33913 (Zip Code) |
| | |
| | |
(239) 768-0600
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| □ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| □ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| □ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| □ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors;Appointment of Certain Officers; Compensatory Arrangements of CertainOfficers. |
Effective as of September 1, 2010, the Company terminated its employment arrangement with Jack G. Spitz as Vice President of Operations. In accordance with our agreement we will pay Mr. Spitz’s base salary and maintain his employee benefits for a six (6) month period from the date of the termination notice. Mr. Spitz’s termination was part of a broader reorganization of the Company’s operations, which we estimate will result in approximately $1.5 million of annual cost savings.
| Item 9.01. | Financial Statements and Exhibits. |
(a) Not applicable
(b) Not applicable
(c) Not applicable
(d) Not applicable
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | NEOGENOMICS, INC. | |
| | | | |
| | By: | /s/ Douglas M. VanOort | |
| | | Douglas M. VanOort Chairman and Chief Executive Officer | |
| | | | |
